Clinical trials: Adenocarcinoma of the Prostate
Prostate Adenocarcinoma
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in patients in whom ADT + radiation therapy is…
- Trial name
- BiolenRT (NCT04943536)
- Testing
- bicalutamide, Stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Alessa Therapeutics Inc.
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate…
- Trial name
- NCT02949284
- Testing
- Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer (Adenocarcinoma)
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.
Patients with unfavorable intermediate-risk prostate cancer will be randomized between 6 versus 12 months of hormone therapy with radiation therapy.
- Trial name
- PCS-XII (NCT06855589)
- Testing
- 6 months of Eligard, 12 months of Eligard, prostate SBRT or prostate brachytherapy with radiation therapy
- Where
- 5 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Charles LeMoyne Hospital
Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
This phase II trial studies how well olaparib works in treating participants with prostate cancer that has not spread to other parts of the body (localized).
- Conditions
- Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT03570476
- Testing
- Olaparib, Radical Prostatectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Prostate Adenocarcinoma
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.
- Trial name
- NCT06257693
- Testing
- enzalutamide
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Alessa Therapeutics Inc.
Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer
Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
The goal of this study is to determine whether the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD® to Recurrence- Directed Therapy (RDT) improves progression-free survival (PFS) compared to RDT…
- Trial name
- RATIONAL (NCT06654336)
- Testing
- Recurrence-directed therapy (RDT), ELIGARD 22.5mg
- Where
- 5 sites in Canada
- Volunteers
- 162 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Prostate Cancer
Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer
RATIONALE: A low-fat, high-fiber diet that includes soy protein may prevent disease progression in patients with hormone-refractory prostate cancer. Nutrition counseling may help motivate patients to follow this diet.
- Trial name
- NCT00082732
- Testing
- behavioral dietary intervention, dietary intervention, therapeutic dietary intervention
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial
This trial studies the changes in long-term physician-scored genitourinary toxicity achieved in prostate cancer patients eligible for stereotactic radiation therapy when both patients and physicians have access to convincing but…
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- GARUDA (NCT04624256)
- Testing
- Discussion, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01949337
- Testing
- enzalutamide, abiraterone, prednisone
- Where
- 539 sites in United States, Canada and 1 more
- Volunteers
- 1,311 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Benign Prostate Hypertrophy(BPH), Prostate Cancer (Adenocarcinoma)
Investigation of the Diagnostic Role of miRNAs in PCa and BPH
Prostate cancer(PCa) is the second most common cause of cancer-related death in men after lung cancer. Diagnostic methods such as measurement of serum Prostate-specific antigen (PSA) levels used in the clinic still cannot…
- Trial name
- NCT06726070
- Where
- Turkey (Türkiye)
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Alanya Alaaddin Keykubat University
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Prostate Adenocarcinoma
Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma
Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.
- Trial name
- BoneMetPETCT (NCT03496844)
- Testing
- F-18 fluciclovine-PET/CT scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Arizona
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer
This clinical trial studies the effects of a dietary intervention prior to surgery (neoadjuvant) in patients with intermediate risk prostate cancer. Changing your diet before surgery may help to improve overall health.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT04985565
- Testing
- Dietary Intervention, Radical Prostatectomy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Hepatocellular Carcinoma
68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
This study aims to evaluate a novel dual-targeted PET imaging tracer, 68Ga-FAPI-PSMA, for the detection and evaluation of solid tumors.
- Conditions
- Prostate Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Solid Tumors
- Trial name
- NCT07639801
- Testing
- 68Ga-FAPI-PSMA, 68Ga-PSMA-617, 68Ga-FAPI-04
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Prostate Adenocarcinoma
Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer
This phase II trial studies the effects of a soy bread versus a wheat bread in improving immune function in participants who are beginning a course of androgen deprivation therapy for prostate cancer.
- Trial name
- NCT03654638
- Testing
- Dietary Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer
The purpose of this study is to determine if the intra-tumoral injection of a subject's own dendritic cells after cryotherapy of the prostate is a safe and effective treatment for advanced prostate cancer.
- Trial name
- CRITICAL (NCT00753220)
- Testing
- VDC2008, Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Bostwick Laboratories
Prostate Cancer
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer.
- Trial name
- STAMPEDE (NCT00268476)
- Testing
- Celecoxib, Docetaxel, Prednisolone
- Where
- 120 sites in Switzerland, United Kingdom
- Volunteers
- 11,992 people
- Sponsor
- Medical Research Council
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body.
- Trial name
- UCDCC#215 (NCT00814788)
- Testing
- Bicalutamide, Everolimus
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Davis